Splice donor site sgRNAs enhance CRISPR/Cas9-mediated knockout efficiency

Author:

García-Tuñón Ignacio,Alonso-Pérez Verónica,Vuelta Elena,Pérez-Ramos Sandra,Herrero María,Méndez Lucía,Hernández-Sánchez Jesús María,Martín-Izquierdo MartaORCID,Saldaña Raquel,Sevilla Julián,Sánchez-Guijo Fermín,Hernández-Rivas Jesús María,Sánchez-Martín Manuel

Abstract

ABSTRACTCRISPR/Cas9 enables the generation of knockout cell lines and null zygotes by inducing site-specific double-stranded breaks. In most cases the DSB is repaired by non-homologous end joining, resulting in small nucleotide insertions or deletions that can be used to construct knockout alleles. However, these mutations do not produce the desired null result in all cases, but instead generate a similar, functionally active protein. This effect could limit the therapeutic efficiency of gene therapy strategies based on abrogating oncogene expression, and therefore needs to be considered carefully. If there is an acceptable degree of efficiency of CRISPR/Cas9 delivery to cells, the key step for success lies in the effectiveness of a specific sgRNA at knocking out the oncogene, when only one sgRNA can be used. This study shows that the null effect could be increased with an sgRNA targeting the splice donor site (SDS) of the chosen exon. Following this strategy, the generation of null alleles would be facilitated in two independent ways: the probability of producing a frameshift mutation and the probability of interrupting the canonical mechanism of pre-mRNA splicing. In these contexts, we propose to improve the loss-of-function yield driving the CRISPR system at the SDS of critical exons.

Publisher

Cold Spring Harbor Laboratory

Reference27 articles.

1. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering

2. Grimm, D. and Kay, M.A. (2007) RNAi and gene therapy: a mutual attraction. Hematol. Am Soc Hematol Educ Progr., 10.1182/asheducation-2007.1.473.

3. RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?

4. Genome Editing: A New Approach to Human Therapeutics

5. Garcia-Tunon, I. , Hernandez-Sanchez, M. , Ordonez, J.L. , Alonso-Perez, V. , Alamo-Quijada, M. , Benito, R. , Guerrero, C. , Hernandez-Rivas, J.M. and Sanchez-Martin, M. (2017) The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia. Oncotarget, 10.18632/oncotarget.15215.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3